Disease | multiple endocrine neoplasia type 1 |
Comorbidity | C0041327|pulmonary tb |
Sentences | 1 |
PubMedID- 23676166 | However, given that there was no acquired drug resistance, the estimated 6.6% relapse rate (95%ci 4.3-10.1) across all three trials might be considered acceptable for a 4-month regimen in patients with non-cavitary pulmonary tb. |
Page: 1